A phase III trial of niraparib in combination with TSR-042 in first-line ovarian cancer
Phase of Trial: Phase III
Latest Information Update: 03 May 2018
At a glance
- Drugs Niraparib (Primary) ; TSR 042 (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- Acronyms FIRST
- 03 May 2018 According to a TESARO media release, this trial is expected to initiate in Q2 2018.
- 14 Nov 2017 New trial record
- 07 Nov 2017 According to a TESARO Inc. media release, this trial is expected to initiate in the first half of 2018.